Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) Short Interest Update

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 3,746,000 shares, an increase of 30.9% from the May 30th total of 2,860,700 shares. Based on an average daily trading volume, of 446,300 shares, the short-interest ratio is currently 8.4 days. Approximately 7.9% of the company’s shares are short sold.

Eyepoint Pharmaceuticals stock traded down $0.06 during midday trading on Friday, hitting $1.52. 389,992 shares of the company were exchanged, compared to its average volume of 677,144. The stock has a fifty day simple moving average of $1.60. The company has a market cap of $161.29 million, a P/E ratio of -2.62 and a beta of 1.75. The company has a current ratio of 1.96, a quick ratio of 1.93 and a debt-to-equity ratio of 1.77. Eyepoint Pharmaceuticals has a fifty-two week low of $1.24 and a fifty-two week high of $3.94.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.03). The company had revenue of $2.01 million for the quarter, compared to analyst estimates of $3.70 million. Eyepoint Pharmaceuticals had a negative return on equity of 195.83% and a negative net margin of 1,739.81%. On average, sell-side analysts predict that Eyepoint Pharmaceuticals will post -0.4 earnings per share for the current fiscal year.

Several equities analysts have recently weighed in on EYPT shares. ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a research note on Thursday, March 21st. Zacks Investment Research lowered Hess Midstream Partners from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th. Finally, HC Wainwright lifted their price objective on Palatin Technologies from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Thursday, May 9th.

In other Eyepoint Pharmaceuticals news, Director John B. Landis purchased 40,000 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were purchased at an average cost of $1.74 per share, with a total value of $69,600.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 18.91% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in Eyepoint Pharmaceuticals by 712.5% during the 4th quarter. BlackRock Inc. now owns 1,232,335 shares of the company’s stock worth $2,329,000 after acquiring an additional 1,080,662 shares in the last quarter. Arcus Capital Partners LLC acquired a new position in Eyepoint Pharmaceuticals during the 1st quarter worth approximately $45,000. Bank of New York Mellon Corp lifted its position in Eyepoint Pharmaceuticals by 78.5% during the 4th quarter. Bank of New York Mellon Corp now owns 51,501 shares of the company’s stock worth $97,000 after acquiring an additional 22,645 shares in the last quarter. Laurion Capital Management LP lifted its position in Eyepoint Pharmaceuticals by 152.5% during the 1st quarter. Laurion Capital Management LP now owns 188,600 shares of the company’s stock worth $338,000 after acquiring an additional 113,900 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Eyepoint Pharmaceuticals by 10.8% during the 4th quarter. Northern Trust Corp now owns 113,544 shares of the company’s stock worth $215,000 after acquiring an additional 11,064 shares in the last quarter. 58.29% of the stock is currently owned by hedge funds and other institutional investors.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.

Read More: What is net income?

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.